Analysts expect that Applied Genetic Technologies Corporation (NASDAQ:AGTC) will report earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Applied Genetic Technologies’ earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.01). Applied Genetic Technologies reported earnings per share of $0.11 in the same quarter last year, which indicates a negative year over year growth rate of 181.8%. The company is expected to announce its next earnings report on Wednesday, February 14th.

According to Zacks, analysts expect that Applied Genetic Technologies will report full-year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($2.45) to ($0.45). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.84) per share, with EPS estimates ranging from ($2.51) to ($0.78). Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Applied Genetic Technologies.

Several brokerages have weighed in on AGTC. Wedbush reissued an “outperform” rating and issued a $9.00 price target on shares of Applied Genetic Technologies in a report on Wednesday, November 8th. Stifel Nicolaus lowered their price target on Applied Genetic Technologies from $15.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, September 14th. ValuEngine downgraded Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. HC Wainwright reissued a “buy” rating and issued a $8.00 price target (down previously from $16.00) on shares of Applied Genetic Technologies in a report on Thursday, September 14th. Finally, Cantor Fitzgerald lowered their price target on Applied Genetic Technologies from $15.00 to $9.00 and set a “neutral” rating for the company in a report on Thursday, September 14th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $10.17.

Shares of Applied Genetic Technologies (NASDAQ AGTC) traded up $0.20 during midday trading on Friday, reaching $4.10. The company’s stock had a trading volume of 191,900 shares, compared to its average volume of 191,133. The firm has a market capitalization of $70.56, a P/E ratio of -20.50 and a beta of 1.62. Applied Genetic Technologies has a fifty-two week low of $3.25 and a fifty-two week high of $10.15.

Several institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Applied Genetic Technologies by 48.1% during the third quarter. Dimensional Fund Advisors LP now owns 394,490 shares of the biotechnology company’s stock valued at $1,558,000 after acquiring an additional 128,049 shares in the last quarter. Citadel Advisors LLC raised its position in Applied Genetic Technologies by 304.6% during the third quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 31,070 shares in the last quarter. ClariVest Asset Management LLC raised its position in Applied Genetic Technologies by 18.5% during the third quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock valued at $391,000 after acquiring an additional 15,491 shares in the last quarter. Nine Chapters Capital Management LLC purchased a new position in Applied Genetic Technologies during the third quarter valued at approximately $113,000. Finally, DAFNA Capital Management LLC raised its position in Applied Genetic Technologies by 2.4% during the second quarter. DAFNA Capital Management LLC now owns 421,000 shares of the biotechnology company’s stock valued at $2,147,000 after acquiring an additional 10,000 shares in the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect Applied Genetic Technologies Corporation (AGTC) Will Post Earnings of -$0.09 Per Share” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/zacks-analysts-expect-applied-genetic-technologies-corporation-agtc-will-post-earnings-of-0-09-per-share/1796157.html.

About Applied Genetic Technologies

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Get a free copy of the Zacks research report on Applied Genetic Technologies (AGTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.